DermTech, Inc. (DMTK)

NASDAQ: DMTK · IEX Real-Time Price · USD
-0.02 (-0.57%)
Mar 20, 2023, 9:30 AM EDT - Market open

Company Description

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States.

It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions.

The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways.

In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies.

The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.

DermTech, Inc.
DermTech logo
Country United States
Industry Diagnostics & Research
Sector Healthcare
Employees 255
CEO Dr. John D. Dobak M.D.

Contact Details

11099 N. Torrey Pines Road, Suite 100
La Jolla, California 92037
United States
Phone 858-450-4222

Stock Details

Ticker Symbol DMTK
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001651944
CUSIP Number 24984K105
ISIN Number US24984K1051
Employer ID 84-2870849
SIC Code 8071

Key Executives

Name Position
Dr. John D. Dobak M.D. President, Chief Executive Officer and Director
Kevin Sun M.B.A. Chief Financial Officer, Treasurer and Secretary
Claudia Ibarra Chief Operating Officer
Ray Akhavan J.D. General Counsel
Todd Michael Wood Chief Commercial Officer
William W. Zondler Chief Information Officer
Steve E. Kunszabo Senior Director of Investor Relations
Jennifer Eilemberg Chief Compliance Officer
Ray Bassi Vice President of Sales
Dr. Burkhard Jansen M.D. Chief Medical Affairs Officer

Latest SEC Filings

Date Type Title
Mar 13, 2023 8-K Current Report
Mar 3, 2023 S-8 Securities to be offered to employees in employee benefit plans
Mar 2, 2023 10-K Annual Report
Mar 2, 2023 8-K Current Report
Feb 14, 2023 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 3, 2023 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 15, 2022 8-K/A [Amend] Current report
Nov 14, 2022 8-K Current Report
Nov 8, 2022 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Nov 3, 2022 10-Q Quarterly Report